|
|
Taiwan Academic Institutional Repository >
Browse by Author
|
"kudo m"
Showing items 66-76 of 76 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
| 臺大學術典藏 |
2018-09-10T18:04:58Z |
Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study
|
Kudo, M.;Cheng, A.-L.;Park, J.-W.;Park, J.H.;Liang, P.-C.;Hidaka, H.;Izumi, N.;Heo, J.;Lee, Y.J.;Sheen, I.-S.;Chiu, C.-F.;Arioka, H.;Morita, S.;Arai, Y.; PO-CHIN LIANG; ANN-LII CHENG |
| 臺大學術典藏 |
2018-09-10T08:13:48Z |
Asian pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma
|
Omata, M.;Lesmana, L.A.;Tateishi, R.;Chen, P.-J.;Lin, S.-M.;Yoshida, H.;Kudo, M.;Lee, J.M.;Choi, B.I.;Poon, R.T.P.;Shiina, S.;Cheng, A.L.;Jia, J.-D.;Obi, S.;Han, K.H.;Jafri, W.;Chow, P.;Lim, S.G.;Chawla, Y.K.;Budihusodo, U.;Gani, R.A.;Lesmana, C.R.;Putranto, T.A.;Liaw, Y.F.;Sarin, S.K.; PEI-JER CHEN; ANN-LII CHENG |
| 國立成功大學 |
2018 |
Ramucirumab safety in East Asian patients: A meta-analysis of six global, randomized, double-blind, placebo-controlled, phase III clinical trials
|
Yen, C.-J.;Muro, K.;Kim, T.-W.;Kudo, M.;Shih, J.-Y.;Lee, K.-W.;Chao, Y.;Kim, S.-W.;Yamazaki, K.;Sohn, J.;Cheng, R.;Zhang, Y.;Binder, P.;Mi, G.;Orlando, M.;Chung, H.C. |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 臺大學術典藏 |
2017 |
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
|
El-Khoueiry A.B.; Sangro B.; Yau T.; Crocenzi T.S.; Kudo M.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Trojan J.; Welling T.H.; 3rd, Meyer T.; Kang Y.-K.; Yeo W.; Chopra A.; Anderson J.; dela Cruz C.; Lang L.; Neely J.; Tang H.; Dastani H.B.; Melero I. |
| 國立臺灣大學 |
2016 |
Safety and preliminary efficacy of nivolumab (nivo) in patients (pts) with advanced hepatocellular carcinoma (aHCC): Interim analysis of the phase 1/2 CheckMate-040 study
|
Melero, I.; Sangro, B.; Yau, T.; Hsu, C.; Kudo, M.; Crocenzi, T.; Kim, T-Y.; Choo, S-P.; Trojan, J.; Meyer, T.; Welling, T. H., III; Yeo, W.; Chopra, A.; Anderson, J.; Dela Cruz, C.; Lang, L.; Neely, J.; El-Khoueiry, A.; 許駿 |
| 國立臺灣大學 |
2016 |
Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study
|
Zhu, A.; Knox, J.; Kudo, M.; Chan, S.; Finn, R.; Siegel, A.; Ma, J.; Watson, P. A.; Cheng, A-L.; 鄭安理 |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
| 國家衛生研究院 |
2014-07-02 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國家衛生研究院 |
2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib
|
Zhu, AX;Kudo, M;Assenat, E;Cattan, S;Kang, YK;Lim, HY;Poon, RTP;Blanc, JF;Vogel, A;Chen, CL;Dorval, E;Peck-Radosavljevic, M;Santoro, A;Daniele, B;Furuse, J;Jappe, A;Perraud, K;Anak, O;Sellami, DB;Chen, LT |
| 國立臺灣大學 |
2012 |
OBSERVATIONS OF HEPATOCELLULAR CARCINOMA (HCC) MANAGEMENT PATTERNS FROM THE GLOBAL HCC BRIDGE STUDY: AN INTERIM ANALYSIS OF HCC BURDEN OF ILLNESS IN THE ASIA-PACIFIC (AP) COHORT
|
Orsini, L. S.; Park, J. W.; Kudo, M.; Chen, P. J.; Chen, M.; 陳培哲 |
Showing items 66-76 of 76 (2 Page(s) Totally)
<< < 1 2
View [10|25|50] records per page
|
